Nexalin Technology Reports Reduction in Self-Injury and Depression Symptoms in Adolescents
Nexalin Technology, Inc. has announced the publication of a peer-reviewed study in BMC Psychiatry, highlighting the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology. The study focused on female adolescents with non-suicidal self-injury (NSSI) and reported statistically significant reductions in self-injury behaviors and depressive symptoms. The research involved six patients who underwent 21 days of 77.5 Hz, 15 mA stimulation using Nexalin's device. Improvements were noted in depressive symptoms and self-injury behaviors, with changes in brain-network activity and connectivity. The study found alterations in emotional-control networks, including Default, Limbic, Salience/Ventral Attention, and Control networks. Nexalin's Chief Medical Officer, David Owens, emphasized the importance of these findings in supporting the mechanism of Nexalin's neurostimulation approach.